Skip Ribbon Commands
Skip to main content
Back to Search Results

A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)

​LOCALLY ADVANCED/ METASTATIC - First Line

Condition: Intervention: Phase:
Lung Cancer II
Status: Open (Show results)
Volunteers Required: Yes
Published Date: 20 October 2020

Term of Use/Disclaimer

All information provided within this web and mobile application is intended for general information and is provided on the understanding that no surgical and medical advice or recommendation is being rendered. Please do not disregard the professional advice of your physician.

Principal Investigator

Senior Consultant

Organised by

National Cancer Centre Singapore
Last updated on